| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Correction to: SB8: A Bevacizumab Biosimilar
|
Syed, Yahiya Y.
|
|
|
16 |
1 |
p. 119
|
article
|
| 2 |
Developing Symptom Lists for People with Cancer Treated with Targeted Therapies
|
Sodergren, Samantha C.
|
|
|
16 |
1 |
p. 95-107
|
article
|
| 3 |
Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib
|
Zheng, Jenny
|
|
|
16 |
1 |
p. 69-76
|
article
|
| 4 |
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile
|
Lorusso, Domenica
|
|
|
16 |
1 |
p. 59-68
|
article
|
| 5 |
Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective
|
Yang, Xinrui
|
|
|
16 |
1 |
p. 1-12
|
article
|
| 6 |
Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis
|
Li, Xiaoyang
|
|
|
16 |
1 |
p. 13-26
|
article
|
| 7 |
Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA
|
Laliberté, François
|
|
|
16 |
1 |
p. 85-94
|
article
|
| 8 |
Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers
|
Watson, Catherine H.
|
|
|
16 |
1 |
p. 109-118
|
article
|
| 9 |
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
|
Delord, Jean-Pierre
|
|
|
16 |
1 |
p. 37-46
|
article
|
| 10 |
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
|
Lebbé, Céleste
|
|
|
16 |
1 |
p. 47-57
|
article
|
| 11 |
The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
|
Buder, Anna
|
|
|
16 |
1 |
p. 77-84
|
article
|
| 12 |
Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib
|
Fazio, Nicola
|
|
|
16 |
1 |
p. 27-35
|
article
|
Journal description